Related Experiment Video
Updated: Jun 22, 2026

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
Published on: February 23, 2024
Fanconi syndrome due to deferasirox
Cédric Rafat1, Fadi Fakhouri, Jean-Antoine Ribeil
1Université Paris Descartes, Hôpital Necker, APHP, Paris, France.
Abstract:
Deferasirox is an innovative iron-chelating treatment. However, preliminary data have suggested that kidney toxicity may be a major issue in the management of patients receiving this drug. We report a case of Fanconi syndrome associated with acute renal insufficiency in a patient receiving deferasirox. The latter has to be added to the expanding list of drugs that may induce Fanconi syndrome. Careful monitoring of kidney function and markers of proximal tubular injury are mandatory in patients undergoing treatment with deferasirox.
Related Concept Videos
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Drug Toxicity: Risk factors
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Heart Failure Drugs: Inotropic Agents
Lysosomal Hydrolases

